Inventurus Knowledge Solutions Limited — Q1 FY26 earnings call

Call held 1 Aug 2025

Management summary

IKS Health reported a strong Q1 FY26 with robust revenue growth of 16% YoY and significant margin expansion, driven by the successful integration of AQuity and operational efficiencies. The company continues to advance its AI-native platform, secure key client wins, and make progress on strategic outcome-oriented deals like Palomar and Western Washington. Despite a material revenue drag from intentional client pruning, profitability metrics saw substantial improvement, and net debt continued to reduce.

Highlights

  • Revenue grew 16% YoY to approximately ₹740 crores, with 13% growth on a constant currency basis, indicating market share gains.

  • EBITDA margin improved significantly to 32% (₹238 crores), a 90 bps improvement QoQ and 36% YoY growth, driven by AQuity integration and efficiency.

  • PAT increased by 59% YoY to approximately ₹151 crores, benefiting from reduced finance costs due to debt repayment.

  • Net debt continued to improve, standing at ₹448 crores at the end of the quarter.

  • The Palomar deal is progressing ahead of plan, and the Western Washington deal (48% MSO stake, 30-year perpetual contract) is a monumental opportunity.

Concerns

  • The intentional pruning of AQuity's small customer base and the transformation of the AQuity install base resulted in a material revenue drag.

  • Employee benefit expense increased to 52.3% of revenues (from 51.8% in the previous quarter) due to technology investments and increments, despite a 7% YoY reduction in headcount.

  • The Effective Tax Rate (ETR) stood at 22% due to the loss of tax breaks in one SEZ unit, expected to remain in this range for the full year.

Key financials

  1. Revenue ₹740 Cr +16%YoY
  2. EBITDA Margin 32% +36%YoY
  3. PAT ₹151 Cr +59%YoY
  4. EPS ₹9 +58%YoY
  5. Net Debt ₹448 Cr
  6. Operating Cash Flow ₹165 Cr
  7. Free Cash Flow ₹137 Cr
  8. Headcount 12,368 FTEs -7%YoY

What they filed

Q1 FY27: revenue up 48.9%, net profit up 44.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue240 241 290 319 356 +48%404 +68%413 +42%475 +49%
EBITDA116 103 129 150 178 +53%196 +90%212 +64%219 +46%
Net profit92 83 100 113 138 +50%146 +76%169 +69%163 +44%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Order book

medium confidence
Management noted momentum in cross-sell, large platform deals, and significant new customer wins, but did not quantify total order book or TCV. The intentional pruning of AQuity's small customer base is ongoing.

Source: Prepared remarks

Capital allocation

high confidence
  • Debt Net ₹448 Cr
    • Repayment Finance cost continues to come down due to debt repayment and lower interest rates.
    Nithya Balasubramanian: "our net debt position stood at Rs. 448 crores and the continued cash generation in the future quarters is where you will continue to see this number improve."
  • M&A AQuity Acquisition · Integrated

    Integration of people, process, technology, and culture is complete, leading to synergies and margin expansion.

    Proforma blended margins dropped from high 30s EBITDA to ~24% post-acquisition, now working to bring back to early to mid-30s.

    Sachin Gupta: "I am happy to report that about nearly 18 months out, we feel like that effort feels complete. We feel like one company. And a lot of synergies associated with that are now evident in our performance."
  • M&A Western Washington Medical Group MSO Joint venture · Signed · Consideration ₹[object Object] (cash)

    Monumental opportunity to participate in value creation, leverage IKS platform with EPIC integration, and create a second set of economics.

    Anticipate +15% revenue upside for the same patient mix and payer mix.

    Sachin Gupta: "invested $17 million to get a 48% stake in the MSO that has a perpetual contract to manage all of the non-clinical operations."
  • Liquidity Liquidity disclosed Operating cash flow was ₹165 crores and free cash flow was ₹137 crores, with a $5 million upfront performance guarantee paid.
    Nithya Balasubramanian: "In terms of operating cash flow, we ended the quarter at Rs. 165 crores and free cash flow came in at Rs. 137 crores. These numbers are net of an upfront performance guarantee we have extended to the tune of $5 million to a multi-specialty primary care organization."

Guidance & targets

Margin

  • EBITDA Margin Margin · over a period of time · High confidence early to mid-30s%
    Sachin Gupta: "I would like to say that I think a large part of that work is moving faster than we had anticipated, which is obviously being reflected in the numbers that we talk about for Q1. So I would say that that sort of part of the work is maybe two-thirds done."

    — Sachin Gupta

Growth

  • Market Share Growth Growth · over a period of time · High confidence >12%
    Sachin Gupta: "And our idea, obviously, is to grow significantly faster than the outsourced TAM over a period of time."

    — Sachin Gupta

Operational

  • AQuity Tail Cutting Completion Operational · next 2-3 quarters / remainder of FY26 · Medium confidence completion
    Sachin Gupta: "I think perhaps another two to three quarters is the way to think about it."

    — Sachin Gupta

  • Palomar Full Platform Implementation Operational · end of fiscal Q2 · High confidence 100% implementation
    Sachin Gupta: "It is totally fair to assume that perhaps by the end of this fiscal, which is fiscal Q2, we would be fully implemented across all the features, across nearly 100% of the physicians at Palomar."

    — Sachin Gupta

Revenue

  • Palomar Peak Platform Fee Revenue Revenue · end of fiscal Q2 · High confidence achieved
    Sachin Gupta: "But yes, on the platform fee, the peak would have been achieved by the end of fiscal Q2."

    — Sachin Gupta

Headcount

  • Headcount Trajectory Headcount · rest of the year · Medium confidence inch up
    Nithya Balasubramanian: "So, I think overall, you will probably see that number inch up in the rest of the year as we continue to support the growth that we have been facing."

    — Nithya Balasubramanian

What to watch in Q2 FY26

AQuity Tail Cutting Completion

next quarter
Current Ongoing, ~2/3 quarters remaining
Target Further progress towards completion

Why it matters

Completion of tail cutting will reduce revenue drag and stabilize the customer base, impacting future growth rates.

Sachin Gupta: "I think perhaps another two to three quarters is the way to think about it."

Risks & concerns

  • Material revenue drag from AQuity tail pruning and transformation

    medium

    Intentional pruning of small AQuity customers and transformation of the install base is causing a material revenue drag, though it's managed to not offset organic growth.

    Management acknowledged

  • Organizational inertia in large health systems hindering AQuity customer migration

    medium

    Large health systems have long decision cycles and organizational inertia, which is a bottleneck for migrating AQuity customers to the full AI-native platform.

    Management acknowledged

  • Loss of tax breaks impacting Effective Tax Rate (ETR)

    low

    Lost tax breaks in one SEZ unit led to an ETR of 22%, which is expected to remain in that range for the full year.

    Management acknowledged

Q&A highlights

6 direct
Top 5 client growth drivers and sustainability Direct
Sachin Gupta: "There is momentum being seen on the cross-sell of AQuity in one of the customers. There are these large platform deals that we have signed that have kicked in into that top 5 and the reality is, Sagar, if you think about it, when I look at the wallet of our top 5 customers, the wallet potential for our platform, we are nowhere near 100%. So, I think one, it's a great sign that the top 5 customers are growing and sure, if we continue to execute like this, there is no reason to believe that the top 5 customer growth should be there.

Clarifies the drivers behind strong growth in top clients and management's confidence in its sustainability due to untapped wallet share.

Asked by Sagar Dhawan

Palomar deal update and upsides Direct
Sachin Gupta: "Yes, I think we are ahead of plan actually. I can't go into the specifics here, but I would like to say that so far, we have been delighted. Our teams have executed tremendously on the deal, even as we are not even fully implemented on all the features of the platform. Our financial pro forma 6 months in is better than what we thought it was going to be, even though we are not fully implemented.

Provides a positive update on a key strategic deal, indicating better-than-expected financial performance even before full implementation.

Asked by Sagar Dhawan

Impact and duration of AQuity tail cutting Direct
Sachin Gupta: "I am comfortable saying that the drag is material and that is why even as we are continuing to be intentional, we are trying to manage the drag in a manner that the cutting of the tail is real, because the reality is that cutting of the tail is also helping with margin growth. But at the same time, it's not so dramatic that it offsets our organic growth, which I think is returning back very strongly.

Acknowledges a 'material drag' on revenue from strategic pruning but assures it's managed to not negate organic growth, while also contributing to margin improvement.

Asked by Sagar Dhawan

Palomar full implementation timeline and peak revenue potential Direct
Sachin Gupta: "It is totally fair to assume that perhaps by the end of this fiscal, which is fiscal Q2, we would be fully implemented across all the features, across nearly 100% of the physicians at Palomar. And so, yes, we would have reached our peak revenue potential at Palomar at that point.

Provides a clear timeline for full implementation and peak platform fee revenue for the Palomar deal, offering visibility into future revenue streams.

Asked by Srinath V

Risk of Palomar acquisition by another entity and vendor consolidation Direct
Sachin Gupta: "So given that we were potentially anticipating a change of control, even when we did the deal, Srinath, we had already built a no out in the event of change of control. So first of all, there's a very penal contractual protection that will probably be a huge deterrent... I think there is more opportunity than risk in Palomar integrating with one of the large systems in the area.

Addresses a potential risk of a key deal, reassuring investors about contractual protections and seeing potential upside if Palomar is acquired by a larger system.

Asked by Srinath V

AQuity customer migration to Ambient AI IKS product and bottlenecks Partial
Sachin Gupta: "No, I think, look, the bottleneck is really organizational inertia more than anything else. And so, these are large health systems that have relatively long decision cycles. And so I would say that we are not near the completion of this transition. And like I was saying earlier, I think just like the cutting of the tail, perhaps has another two to three quarters of runway. I think the remainder of this fiscal year is probably a good way to think about when that transition might be completed.

Identifies organizational inertia and long decision cycles in large health systems as the primary bottleneck for AQuity customer migration, providing a timeline for completion.

Asked by Srinath V

Sustainability of employee count reduction and future scope Partial
Nithya Balasubramanian: "So, you will obviously see a balance in terms of our continued optimization of the legacy equity workforce. I think like Sachin pointed out, there is at least another two to three quarters where we will continue to optimize and we deploy our technology and achieve the right balance between on-shoring and off-shoring. However, we are of course growing, even as I say that at the same time, we are also growing significantly in other parts of the business. And therefore, we do need to support that growth with additional employees, both in terms of technologies as well as other administrative employees. So, I think overall, you will probably see that number inch up in the rest of the year as we continue to support the growth that we have been facing.

Clarifies that while optimization of the legacy workforce will continue for 2-3 more quarters, overall headcount is expected to 'inch up' due to growth in other business areas requiring new hires.

Asked by Nilesh Jain

EBITDA margin expansion beyond mid-30s Direct
Sachin Gupta: "Look, I think we have said continuously that we expect to get somewhere in the early to mid-30s. As you can see, we are already past the early 30s, almost well ahead of what we had said. And so I just still maintain that, Nilesh, that we will see ourselves getting to early to mid-30s and we think margins should stabilize at that rate. To try and say that margins could improve beyond the early to mid-30s, I don't feel comfortable saying that.

Sets realistic expectations for EBITDA margins, indicating that while the company is confident in reaching the early to mid-30s, further expansion beyond that is not currently anticipated.

Asked by Nilesh Jain

3 min read 6 chapters

Detailed narrative

Q1 FY26 Financial Performance Highlights

Inventurus Knowledge Solutions Limited reported a strong Q1 FY26, with revenue reaching approximately ₹740 crores, marking a 16% year-on-year growth (13% in constant currency). The company achieved an EBITDA margin of 32%, translating to approximately ₹238 crores, which represents a 36% YoY increase. PAT grew significantly by 59% YoY to about ₹151 crores, driven by both operational efficiencies and a reduction in finance costs from ₹26 crores in Q1 FY25 to ₹18 crores in Q1 FY26. EPS stood at ₹9, up 58% YoY and 2% QoQ, with a healthy Return on Equity of 31%.

Strategic AI-Native Platform Evolution

The company made significant strides in its AI-native, agentic platform strategy, launching 'Scribble Now' for fully ambient, autonomous clinical documentation. This includes a multi-variant Scribble option allowing physicians to choose different variants for different visit types. IKS also expanded its Gen AI-led autonomous medical coding technology to two specialties and is progressing in denial prediction/prevention and AI-led patient engagement. This strategic shift aims to move towards fully autonomous features, reducing reliance on human-in-the-loop models over time.

AQuity Integration and Operational Efficiency

Eighteen months post-acquisition, the integration of AQuity is largely complete, with management noting that the effort 'feels complete' and synergies are evident in performance. While the transformation of AQuity's delivery model from human-led to technology-led has caused a 'material drag' on revenue per unit, it has significantly improved margins. The company's global headcount decreased by 7% YoY to 12,368 FTEs, demonstrating non-linearity in growth, as revenue increased by 16% with fewer employees.

Key Client Wins and Outcome-Oriented Deals

IKS secured significant client wins, including Sky Lakes Health System for full platform adoption (ambulatory and acute RCM end-to-end), making it the second end-to-end acute RCM customer. New relationships were formed with Bicycle Health, a PE-owned behavioral health platform, and an expanded partnership with OrthoNY to a full-platform thesis. The Palomar deal, a 15-year contract, is progressing 'tremendously ahead of plan,' and the Western Washington deal, involving a $17 million investment for a 48% MSO stake and a 30-year perpetual contract, is expected to yield a +15% revenue upside.

Capital Structure and Debt Reduction

The company's net debt continued its improving trend, standing at ₹448 crores at the end of Q1 FY26. This reduction, coupled with lower interest rates, contributed to a decrease in finance costs from ₹26 crores in Q1 FY25 to ₹18 crores in the current quarter, significantly boosting PAT growth. Operating cash flow for the quarter was ₹165 crores, with free cash flow at ₹137 crores, after accounting for a $5 million upfront performance guarantee.

Outlook on Margins and Headcount

Management expressed confidence in achieving EBITDA margins in the 'early to mid-30s' range, noting that the company is already past the early 30s. While the optimization of the legacy AQuity workforce is expected to continue for another two to three quarters, overall headcount is projected to 'inch up' in the rest of the year to support growth in other business areas. The Effective Tax Rate is expected to remain around 22% for the full year due to the loss of tax breaks in one SEZ unit.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Information Technology earnings calls